New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
Includes global rights to generic Advair® Diskus and Seretide® Diskus PITTSBURGH, Nov. 9, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into an agreement with ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 14, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from ...
Novartis International AG / AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus® [1] in persistence to treatment . Processed and transmitted by Nasdaq Corporate Solutions. The ...
PITTSBURGH, Nov. 9, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and ...
GlaxoSmithKline plc and Theravance, Inc. today announced positive results from three phase III studies. Two studies comparing the efficacy and safety of the combination anticholinergic / long-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback